HYL
General Information
DRACP ID DRACP01204
Peptide Name HYL
Sequence GIMSSLMKKLAAHIAK
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin AMP
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
A549 | Lung adenocarcinoma | Carcinoma | IC50=10.01±0.34 µmol/L | MTT assay | 72h | Patent |
Hep-G2 | Hepatoblastoma; Hepatoblastoma | Blastoma | IC50=14.71±0.42 µmol/L | MTT assay | 72h | Patent |
HCT 116 | Colon carcinoma | Carcinoma | IC50=22.89±0.22 µmol/L | MTT assay | 72h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C75H135N21O19S2
Absent amino acids CDEFNPQRTVWY
Common amino acids AK
Mass 196690
Pl 11.1
Basic residues 4
Acidic residues 0
Hydrophobic residues 7
Net charge 4
Boman Index 264
Hydrophobicity 55.63
Aliphatic Index 116.25
Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Structural modification and antitumor activity of antimicrobial peptide HYL
Doi 10.1016/j.cclet.2019.10.013
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available